Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding

Table 5

Factors related to the development of hepatic encephalopathy in patients with cirrhosis after an acute episode of variceal bleeding. Multivariate analysis by Cox regression models.

MODEL 1
Characteristic	OR (95 CI)	P
Recurrence of bleeding (yes)	1.9 (0.8 – 4.5)	0.17
Decompensated cirrhosis (Child-Pugh B or C)	1.0 (0.4 – 3.0)	0.96
Primary prophylaxis with any anti-ammonium drug	0.6 (0.2 – 1.5)	0.28
MODEL 2
Characteristic	OR (95 CI)	P
Recurrence of bleeding (yes)	1.6 (0.6 – 4.4)	0.39
Cirrhosis (Child-Pugh A)	-	0.50
(i) Child-Pugh B	0.8 (0.2 – 2.8)	0.76
(ii) Child-Pugh C	1.7 (0.4 – 7.3)	0.46
Group of Treatment (Placebo)	-	0.69
(i) LOLA	0.6 (0.2 – 2.3)	0.47
(ii) Lactulose	0.5 (0.2 – 1.7)	0.26
(iii) Rifaximin	0.6 (0.2 – 2.0)	0.41

CI: confidence interval; LOLA: L-ornithine L-aspartate; OR: odds ratio.
Statistical significance: P 0.05.